## REMARKS

After entry of this amendment, the claims now pending are claims 1, 32, 33, 35-37, 39, 44 and 46.

## A. Status of the Claims

Claims 2-7, 9-15, 17, 19-20, 22-23, 26 and 28-30 were previously canceled. Applicant reserves the right to prosecute the canceled claims in a continuation application filed during the pendency of this application. Non-elected claims 8, 16, 18, 21, 24, 25, 27, 31, 34, 38, 40-43, and 45 are now canceled.

Claims 1, 32, 33, 35-37, 39, and 44 are amended to remove non-elected subject matter and to correct clerical errors. Applicant reserves the right to prosecute all non-elected subject matter and non-elected claims in a divisional application filed during the pendency of this application. Applicant has also added new claim 46 which provides for the nucleic acid sequence encoding for the KLK-L2 protein SEQ ID NO: 14. This claim is supported throughout the specification and particularly in FIG. 7 which illustrates the exon and intron sequences of SEQ ID NO: 13. When the exons are spliced together, and the introns removed, the nucleic acid sequence formed of spliced fragments of SEQ ID NO: 13 encodes the protein of SEQ ID NO: 14. No new matter is added by these amendments.

## B. Elections

In response to the outstanding Restriction Requirement, Applicant elects the claims of Group 1, i.e., claims 1, 32, 33, 35-37, 39, 44 and 46 drawn to an isolated nucleic acid of the KLK gene, a vector comprising said nucleic acid, a host cell comprising said nucleic acid, a method of preparing a protein by culturing the host cell transformed with said vector and a composition comprising said nucleic said acid. Applicant notes that claim 27, which depended from claim 44, was included with the claims of Group I. However, since claim 27 should properly depend from claim 43, it was deleted as being drawn to a non-elected embodiment. New claim 46 is believed to fall within the scope of Group I claims, and is thus elected.

In response to the requirement to elect one (1) specific sequence, Applicant elects the nucleic sequence and encoded amino acid sequence of the KLK-L2 nucleic acid molecule, i.e., SEQ ID NOs: 13 and 14, respectively. Note that in





order to make the election, both sequences must be referenced. As stated above, SEQ ID NO: 14 is the result of the splicing of the exons of the KLK-L2 nucleic acid sequence SEQ ID NO: 13, as is shown illustratively in FIG. 7.

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to our Deposit Account Number 08-3040.

Respectfully submitted,

**HOWSON AND HOWSON** Attorneys for Applicant

Mary E. Bak
Registration No. 31,215

Spring House Corporate Center

Box 457

Spring House, PA 19477

(215) 540-9200